Vanguard Group Inc Lineage Cell Therapeutics, Inc. Put Options Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding LCTX
# of Institutions
124Shares Held
93.5MCall Options Held
21.4KPut Options Held
0-
Broadwood Capital Inc New York, NY41.7MShares$38.3 Million4.66% of portfolio
-
Black Rock Inc. New York, NY8.49MShares$7.81 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA6.25MShares$5.75 Million0.86% of portfolio
-
Defender Capital, Llc.4.97MShares$4.57 Million2.61% of portfolio
-
Geode Capital Management, LLC Boston, MA3.25MShares$2.99 Million0.0% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $156M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...